Genetic Engineering & Biotechnology News

MAY15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/819033

Contents of this Issue

Navigation

Page 16 of 37

REVEAL GREATER COVERAGE DEPTH IN WES Achieve greater coverage depth from less sequencing through the enhanced coverage of the new SeqCap EZ MedExome Target Enrichment Kit for whole exome sequencing (WES). Rely on a design developed to enrich the entire exome, but particularly optimized for analyzing genes of medical relevance (Figure 1) in research studies. • Focus on genomic regions that really matter For disease-associated genes, 98% of bases are covered at ≥20X depth. • Call variants with confidence Detect SNPs with 98% sensitivity and >99% specificity for SNP allele classification. • Gain greater efficiency at minimal cost Reduce sequencing cost through uniform coverage and fully supported multiplexing protocols. Reveal more about the exome Learn how the SeqCap EZ MedExome Target Enrichment Kit can improve your whole exome sequencing by visiting sequencing.roche.com/medexome.html or calling 800 262 4911. For life science research only. Not for use in diagnostic procedures. NIMBLEGEN and SEQCAP are trademarks of Roche. All other product names and trademarks are the property of their respective owners. © 2016 Roche PP-US-05143-0816 0.0 10.0 20.0 30.0 40.0 50.0 60.0 <90% 90-97% 97-100% 100% Percent of total GeneTests genes covered Percent of each GeneTests gene's coding bases covered at ≥20X Roche MedExome Supplier A's Clinical Research Exome Figure 1. With SeqCap EZ MedExome, 53% of medically relevant genes are covered at 100% (≥20X coverage) vs. 6% by Supplier A's Clinical Research Exome. Percentage of bases covered at ≥20X for each consolidated target was determined using GATK (DepthOfCoverage), summarized by gene. Supplier A kit's data was generated by a third-party sequencing service provider, following Supplier A's protocol. All reads were subsampled to 60 million for assessment, then subjected to the same bioinformatics pipeline for analysis. Roche data on file.

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - MAY15 2017